Knight Therapeutics Inc.
GUD.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 142.89% | -99.13% | -203.61% | -15.84% | -59.80% |
| Total Depreciation and Amortization | 19.85% | -3.88% | 6.34% | -3.53% | -46.01% |
| Total Amortization of Deferred Charges | 2.25% | -- | -- | -- | 35.60% |
| Total Other Non-Cash Items | -142.00% | 381.59% | 91.38% | -27.08% | 1,990.24% |
| Change in Net Operating Assets | -324.29% | -49.41% | -5.12% | 204.24% | 77.17% |
| Cash from Operations | -92.04% | -67.48% | 28.25% | 617.80% | 169.68% |
| Capital Expenditure | -23.42% | -62.06% | -327.55% | -634.46% | 80.41% |
| Sale of Property, Plant, and Equipment | -94.95% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 631.59% | -67.47% | 180.19% | -174.64% | 94.62% |
| Cash from Investing | 1,022.76% | -68.30% | 174.72% | -180.52% | 97.08% |
| Total Debt Issued | -- | -39.47% | -48.23% | -15.77% | -100.00% |
| Total Debt Repaid | 34.14% | 9.37% | -34.47% | -75.00% | 6.47% |
| Issuance of Common Stock | 47.37% | 409.09% | 223.81% | -19.57% | -15.18% |
| Repurchase of Common Stock | 73.01% | 74.84% | 91.10% | -- | -119.75% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 36.70% | 40.82% | 13.47% | -49.59% | -144.75% |
| Cash from Financing | 58.20% | 65.64% | 49.52% | 75.52% | -227.33% |
| Foreign Exchange rate Adjustments | 112.76% | 399.38% | -229.96% | -43.45% | 267.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 133.08% | -67.82% | 89.16% | 126.44% | 38.25% |